Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Frank Buck who wrote (1183)	1/17/1998 9:57:00 PM
From: Cisco	Read Replies (1) \| Respond to of 1894

®This strategic move allows AccuMed to reduce the portion of its operational costs dedicated to continuing cytopathology R&D and adds significant credibility to the AccuMed strategy.¯ Frank, How much cost savings are we talking about and how soon will it be realized? Cisco

To: Frank Buck who wrote (1183)	1/17/1998 10:40:00 PM
From: CARYTRE	Read Replies (1) \| Respond to of 1894

FRANK CISCO, WHAT DO YOU THINK OF THE FLUFF ANALYSIS. I THINK ITS SIGNIFICANT, BECAUSE IN ADDITION TO BEING THE BEST VALUE BY FAR,IT SHOWS THE THAT ACMI HAS THE HIGHEST RETURN ON EQUITY WHEN INCOME STARTS ROLLING IN.

To: Frank Buck who wrote (1183)	1/17/1998 11:11:00 PM
From: Cisco	Respond to of 1894

Frank, A few thoughts on Oncometrics. Note the following from Oncometrics' web site: ®Oncometrics Imaging Corp. is a scientific research and development company dedicated to the early detection of cancer and precancerous conditions. Oncometrics is a leader in the field of quantitative microscopy. Quantitative microscopy is a powerful scientific research tool, which applies complex computer algorithms to measurements of cell nuclei on a microscope slide to derive medically significant information. Oncometrics, in collaboration with AccuMed International Inc., and the Cancer Imaging Dept. of the BC Cancer Agency, applies this technology to multiple cancer types to enable earlier detection of cancer than is currently possible.¯ oncometrics.com The Cooperative Research Centre for Signal and Information Processing (CSSIP) in a cooperative agreement with the Oncometrics Imaging Corporation has a major 4 year old project underway at the Unviersity of Queensland directed toward the detection of malignancy associated changes (MACS). cssip.edu.au They state that: In the near future we aim to produce the technology for a machine which will screen Pap smear slides by assigning them a MACs score. Low values of this score will indicate with a high probability that the smear is normal whereas high scores will indicate that a malignant potential for cervical cancer exists. In the future we hope to extend this technique to other cancers. cssip.elec.uq.oz.au Research is also going forward at the Cancer Imaging - BC Cancer Research Centre: ®The only non-invasive method of detecting the presence of early lung cancer and precancerous lesions in the lung is sputum cytology. Cancer Imaging in collaboration with a local Vancouver company, Oncometrics Imaging Corp., have developed a fully automated high resolution quantitative microscopy system (CytoSavant) to enable detailed automatic measurements of the DNA in cell nuclei. This system enables one to not only measure DNA amounts in cells but the size, shape, and texture (organization of DNA in cell) of the DNA in the cell nuclei. This makes possible the detection of MAC (Malignancy Associated Changes) in the obstensively normal cells of a tissue surrounding a cancerous lesion. The traditional problem with sputum cytology has been the lack or obviousness of diagnostic cells in the sample. In pilot studies using automated cell analysis for the detection of abnormal cells and the MAC changes in normal cells, a sensitivity of 70-88% has been achieved. Together with Oncometrics, we have started a multi-center sputum analysis field study to clinically demonstrate the sensitivity and specificity of such an approach. Using both the LIFE device and the CytoSavant, our group is studying the natural history of lung neoplasia from its origins in normal tissue through hyperplasia, metaplasia, dysplasia, CIS to invasive carcinoma. We have quantitated the physical nuclear changes, the changes in the tissue architecture (using recently developed cellular sociology tools), and some of the genetic changes (using microdissection techniques with PCR for LOH detection) in collaboration with Dr. Adi Gazdar and Dr. John Minna of UTSMC. We are using results of these studies to perform intermediate biomarker endpoint based chemoprevention studies with subjects at high risk of developing lung cancer as well as to simulate the 3D development of neoplasias in bronchial epithelial tissue using a dynamic 3D model of bronchial epithelial tissue. Other projects underway involve the use of these techniques in the cervix, bladder, larynx, breast and prostate as well as applied physics and engineering to the development of breast cancer screening methodologies, tissue transplantation issues and the improvement of quantitative microscopy.¯ bccancer.bc.ca If AcCell-Savent is able to diagnose pre-cancerous lesions, who is going to be worried about primary screeners? accumed.com Cisco